SHAREHOLDER ALERT: Levi & Korsinsky, LLP Announces the Commencement of an Investigation Into Possible Securities Fraud Violat...
22 Juin 2016 - 9:34PM
Business Wire
Levi & Korsinsky announces it has commenced an investigation
of Insmed Incorporated (“Insmed” or the “Company”) (NASDAQ:INSM)
concerning possible violations of federal securities laws.
On June 8, 2016, Insmed announced that it had withdrawn a
European marketing application submitted to the European Medicines
Agency (“EMA”) for its drug ARIKAYCE. The Company stated that the
marketing application was based on data from a mid-stage clinical
study that “did not provide a sufficient amount of evidence to
support an approval.” Insmed stated that the Company will resubmit
the application when data is available from a later study.
Following this news, shares of Insmed have fallen from a close of
$12.01 per share on June 8, 2016, to a recent close of $9.73 per
share on June 21, 2016. To obtain additional information about the
investigation, go to:
http://zlk.9nl.com/insmed
or contact Eduard Korsinsky, Esq. either via email at ek@zlk.com
or by telephone at (212) 363-7500, toll-free: (877) 363-5972.
Levi & Korsinsky is a national firm with offices in New
York, New Jersey, California, Connecticut, and Washington D.C. The
firm’s attorneys have extensive expertise and experience
representing investors in securities litigation involving financial
fraud, and have recovered hundreds of millions of dollars for
aggrieved shareholders. Attorney advertising. Prior results do not
guarantee similar outcomes.
View source
version on businesswire.com: http://www.businesswire.com/news/home/20160622006358/en/
Levi & Korsinsky, LLPEduard Korsinsky, Esq.Tel:
212-363-7500Toll Free: 877-363-5972Fax: 212-363-7171www.zlk.com
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juin 2024 à Juil 2024
Insmed (NASDAQ:INSM)
Graphique Historique de l'Action
De Juil 2023 à Juil 2024